Clinical Trials Search
Clinical Trial 18992
Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT02775851
Phase: Phase II
Prinicipal Investigator: Zeynep Eroglu
Study Title
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)
Summary
The purpose of this study is to test any good and bad effects of the study drug MK-3475 (also called pembrolizumab).
Objective
1.1 Primary Objective: a.) Cohort A - To evaluate the pathologic complete response rate (pCR as defined in Section 10.0) in patients with resectable desmoplastic melanoma treated with neoadjuvant MK-3475 (pembrolizumab). b.) Cohort B - To evaluate the complete response rate (confirmed and unconfirmed) in patients with unresectable desmoplastic melanoma treated with MK-3475 (pembrolizumab). 1.2 Secondary Objectives: Cohort A a.) To estimate the 9 week response rate (RR) (unconfirmed complete and partial responses). b.) To estimate the median overall survival (OS). c.) To evaluate safety and tolerability of MK-3475 (pembrolizumab) in the neoadjuvant setting. Cohort B d.) To estimate the median progression-free survival (PFS). e.) To estimate the median overall survival (OS). f.) To evaluate safety and tolerability of MK-3475 (pembrolizumab) in this setting. 1.3 Other Objectives (all patients): a.) To evaluate the hypothesis that higher mutational load in the patient derived baseline tumor biopsy samples is associated with higher response rate (RR). b.) To evaluate T cell infiltration into the tumors in DM patients and correlate with response to PD-1 blockade. c.) To evaluate the clonality of tumor infiltrating T cells in DM patients and correlate with response to PD-1 blockade. d.) To evaluate adaptive immune resistant mechanism in DM tumors.
Therapies
Medications
Pembrolizumab (Keytruda)
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.